OCUGEN INC. - COMMON

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 апр 2024 07:02:26 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 апр 2024 06:30:43 Источник Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 апр 2024 07:02:21 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 апр 2024 08:00:39 Источник Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 апр 2024 18:08:46 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 апр 2024 17:43:45 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 мар 2024 06:30:50 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 мар 2024 08:00:54 Источник Nasdaq GlobeNewswire

Ocugen to Present at Investing in Cures Summit

06 мар 2024 07:30:09 Источник Nasdaq GlobeNewswire

Ocugen Clinical Showcase Webcast Now Available

28 фев 2024 08:00:26 Источник Nasdaq GlobeNewswire

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26 фев 2024 08:30:13 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

22 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Ocugen to Present at 2024 BIO CEO & Investor Conference

21 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

14 фев 2024 07:30:49 Источник Nasdaq GlobeNewswire

Ocugen to Present at Pharma Market Research Conference

31 янв 2024 08:00:12 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

16 янв 2024 07:30:58 Источник Nasdaq GlobeNewswire

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

21 дек 2023 06:30:09 Источник Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

19 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

13 дек 2023 07:30:14 Источник Nasdaq GlobeNewswire

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

29 ноя 2023 07:30:12 Источник Nasdaq GlobeNewswire